Thai H. Ho
Expertise in
17
conditions

Dr. Thai H. Ho

Hematology Oncology | Oncology
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
17
conditions
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 

Overview

Dr. Thai Ho has been caring for patients affected by genitourinary cancers for over 10 years. His area of expertise and the focus of his research is in treating kidney and bladder cancers. He also sees patients with kidney, bladder, upper tract urothelial, and prostate cancers, as well as patients affected by hereditary cancer syndromes. Dr. Ho completed the Baylor College of Medicine Physician Scientist Program in 2006, internal medicine residency at Washington University in St. Louis in 2009, and Medical Oncology Fellowship at MD Anderson Cancer Center in 2012.Dr. Ho's research is funded by the National Institutes of Health and Department of Defense to better match cancer patients with targeted therapies by using precision medicine approaches to identify a cancer's unique vulnerabilities. At MUSC Hollings Cancer Center, Dr. Ho is the Director of Precision Medicine and an Associate Professor in the Division of Hematology \& Oncology. Prior to joining MUSC, Dr. Ho was an Associate Professor faculty the Mayo Clinic where he was a member of the Center for Individualized Medicine Epigenomics Group, Genomic Tumor Board, and von Hippel-Lindau Clinic.

Dr. Ho is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Orchiectomy.

He is actively involved in clinical research, co-authoring 101 peer reviewed articles and participating in 7 clinical trials. Dr. Ho is currently accepting new patients.

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in MO

Fellowships

MD Anderson Cancer Center: Medical Oncology, 2012

Hospital Affiliations

Tidelands Georgetown Memorial Hospital
Musc Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

MUSC Health Hematology Oncology at Hollings Cancer Center
86 Jonathan Lucas St, 2nd Floor, 3rd Floor, Charleston, SC 29425

Additional Areas of Focus

Dr. Ho has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Penile Cancer
Prostate Cancer
Bladder Cancer
Testicular Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drug: Gemcitabine and Cisplatin
Study Phase: Phase 2
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454
Enrollment Status: Completed
Publish Date: May 01, 2025
Intervention Type: Drug
Study Drugs: TP-1454 Alone, TP-1454 Combination Therapy
Study Phase: Phase 1
A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 2
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60mg/m2 Administered During a 60 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 80mg/m2 Administered During a 80 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors.
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60mg/m2 Administered During a 60 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 80mg/m2 Administered During a 80 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

101 Total Publications

On the Discorhabdins Leading to the Aleutianamine Ring System: A One-Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology.
On the Discorhabdins Leading to the Aleutianamine Ring System: A One-Step in Situ Transformation Characterized Through Computational and Experimental Studies and Its Implications on Biosynthesis, Synthesis, and Pharmacology.
Journal: Angewandte Chemie (International ed. in English)
Published: December 11, 2025
Similar Doctors
Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.2 miles away)
843-792-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Lindhorst is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Lindhorst is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy. Dr. Lindhorst is currently accepting new patients.

Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.2 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
11
conditions
Dr. Abirami Sivapiragasam
Hematology Oncology | Oncology
Expertise in
11
conditions
Dr. Abirami Sivapiragasam
Hematology Oncology | Oncology
Referral may be required

MUSC Health Hematology Oncology At Hollings Cancer Center

86 Jonathan Lucas St, 2nd Floor, 3rd Floor, 
Charleston, SC 
 (0.1 miles away)
843-792-9300
Languages Spoken:
English, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Abirami Sivapiragasam is a board-certified hematologist and oncologist with over a decade of experience. Currently, she is the Director of Medical Oncology at the MUSC Hollings Cancer Center and an Associate Professor of Medicine at the Medical University of South Carolina. Previously, she worked as an Associate Professor of Medicine at the SUNY Upstate Medical University Hospital in Syracuse, NY. During her tenure there, she also served as the Program Director for the Hematology and Oncology Fellowship program.Dr. Sivapiragasam is an expert in the diagnosis and treatment of breast cancer. She is also a skilled educator, having trained medical students, residents, and fellows.As a member of the American Society of Clinical Oncology and the American Board of Internal Medicine, Dr. Sivapiragasam is committed to keeping up with the latest advancements in her field. Additionally, she is a published researcher in her area of expertise.Dr. Sivapiragasam is known for her compassionate and dedicated approach to patient care. She is a respected leader in the field of breast oncology and is highly regarded in the medical community. Dr. Sivapiragasam is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Angiosarcoma, Laryngeal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Sivapiragasam is currently accepting new patients.

Frequently Asked Questions about Dr. Thai H. Ho

How do I make an appointment with Dr. Thai H. Ho?

You can book an appointment with Dr. Thai H. Ho by calling their office at 843-792-9300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thai H. Ho a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thai H. Ho is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thai H. Ho specialize in?

While Dr. Thai H. Ho is a Hematology Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Thai H. Ho participate in research or clinical trials?

Yes. Dr. Thai H. Ho has published 101 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Thai H. Ho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thai H. Ho accept my insurance?

Dr. Thai H. Ho accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-792-9300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ho's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile